Fig. 5.

Final results of the voting on case scenario 4, psoriasis therapies that potentially reduce cardiovascular morbidity and mortality. a denotes P < 0.05 compared with MTX-TNFI therapy; b denotes P < 0.01 compared with MTX therapy; c denotes P < 0.05 compared with TNFI therapy; d denotes P < 0.01 compared with TNFI (etanercept preferred) therapy; e denotes P < 0.01 compared with TNFI (adalimumab preferred) therapy. MTX methotrexate; pref preferred; TNFI tumor necrosis factor inhibitor; UVB-NB narrowband ultraviolet B therapy